In a real‐world database of metastatic colorectal cancer (mCRC) in the United States, comprehensive genomic profiling (CGP) using plasma‐based next‐generation sequencing identified potentially actionable profiles for approximately one‐third of the patients with both the first test and again with a second test after disease progression, with around 60% of all patients tested receiving therapy consistent with the CGP results at each line of treatment. This suggests a role for CGP prior to more than one line of mCRC treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10823270 | PMC |
| http://dx.doi.org/10.1111/cas.16016 | DOI Listing |
Publication Analysis
Top Keywords
comprehensive genomic
8
genomic profiling
8
metastatic colorectal
8
colorectal cancer
8
serial comprehensive
4
profiling next-generation
4
next-generation sequencing
4
sequencing patients
4
patients metastatic
4
cancer real‐world
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!